NCT02864992

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2016-09-13Est. Completion: 2022-05-16

Enrollment target: 337 participants

Locations

City of Hope Cancer Center, Duarte, California, United States
California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
St. Joseph Hospital, Orange, California, United States
Torrance Health Association, Redondo Beach, California, United States
St Joseph Heritage Healthcare, Santa Rosa, California, United States
Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States
University Cancer & Blood Center, LLC, Athens, Georgia, United States
Winship Cancer Institute, Atlanta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Ingalls Hospital, Harvey, Illinois, United States
Community Regional Cancer Care, Indianapolis, Indiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
For Recruiting Locations in the United States, please Contact U.S. Medical Information, Rockland, Massachusetts, United States

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.